Blinatumomab improves outcomes in infant ALL
Nature Reviews Clinical Oncology, Published online: 11 May 2023; doi:10.1038/s41571-023-00780-zBlinatumomab improves outcomes in infant ALL (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 11, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
ROAR brings in a new histology-agnostic approval for rare cancers
Nature Reviews Clinical Oncology, Published online: 11 May 2023; doi:10.1038/s41571-023-00778-7ROAR brings in a new histology-agnostic approval for rare cancers (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 11, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Gut microbiota in colorectal cancer development and therapy
Nature Reviews Clinical Oncology, Published online: 11 May 2023; doi:10.1038/s41571-023-00766-xEmerging data indicate a central role for the microbiota in all aspects of colorectal cancer (CRC). Despite this general consensus, understanding the role of specific components of the microbiota in such a way that enables the development of clinical interventions or tools to inform clinical decision-making has thus far proved challenging. In this Review, the authors summarize the role of the microbiota in CRC, including in prevention, in interactions with treatment and as a source of novel biomarkers. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 11, 2023 Category: Cancer & Oncology Authors: Chi Chun Wong Jun Yu Source Type: research
Personalizing neoadjuvant immune-checkpoint inhibition in patients with melanoma
Nature Reviews Clinical Oncology, Published online: 05 May 2023; doi:10.1038/s41571-023-00760-3Neoadjuvant immune-checkpoint inhibition is a promising emerging treatment strategy that potentially enables patients with a good response to initial therapy to avoid further treatment and the associated toxicity risks, while also identifying those who might require treatment escalation. In this Review, the authors describe treatment personalization strategies based on the initial response to one or more neoadjuvant immune-checkpoint inhibitors and consider the potential to expand this approach beyond patients with melanoma. (Sou...
Source: Nature Reviews Clinical Oncology - May 5, 2023 Category: Cancer & Oncology Authors: Minke W. Lucas Judith M. Versluis Elisa A. Rozeman Christian U. Blank Source Type: research
HSCT prolongs remission of high-risk CTCLs
Nature Reviews Clinical Oncology, Published online: 05 May 2023; doi:10.1038/s41571-023-00777-8HSCT prolongs remission of high-risk CTCLs (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 5, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Zolbetuximab moves into the SPOTLIGHT
Nature Reviews Clinical Oncology, Published online: 03 May 2023; doi:10.1038/s41571-023-00773-yZolbetuximab moves into the SPOTLIGHT (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 3, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
From AACR 2023
Nature Reviews Clinical Oncology, Published online: 02 May 2023; doi:10.1038/s41571-023-00771-0From AACR 2023 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - May 2, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Biliary tract cancer: frontline pembrolizumab hits KEYNOTE
Nature Reviews Clinical Oncology, Published online: 27 April 2023; doi:10.1038/s41571-023-00772-zBiliary tract cancer: frontline pembrolizumab hits KEYNOTE (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 27, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Improving outcomes in patients with oesophageal cancer
Nature Reviews Clinical Oncology, Published online: 21 April 2023; doi:10.1038/s41571-023-00757-yOesophageal cancer is one of the most common malignancies worldwide and is associated with considerable morbidity and mortality. In this Review, the authors highlight advances made across the disease continuum that have improved the management and outcomes of patients with oesophageal cancer. These advances include an increased understanding of the disease biology, improvements in screening, the development of minimally invasive endoscopic monitoring and management technologies, refinement of surgical techniques and perioperati...
Source: Nature Reviews Clinical Oncology - April 21, 2023 Category: Cancer & Oncology Authors: Manish A. Shah Nasser Altorki Pretish Patel Sebron Harrison Adam Bass Julian A. Abrams Source Type: research
Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours
Nature Reviews Clinical Oncology, Published online: 21 April 2023; doi:10.1038/s41571-023-00756-zAntibody–drug conjugates (ADCs) have demonstrated efficacy in patients with various cancers, although their antitumour activity in the central nervous system (CNS) might be limited by the blood–brain barrier. In this Review, the authors describe the available clinical data emphasizing the heterogeneous activity of ADCs against primary or secondary brain tumours and ongoing clinical trials in this area. In addition, they discuss physical, biological and molecular determinants of the CNS activity of ADCs, as well as potential...
Source: Nature Reviews Clinical Oncology - April 21, 2023 Category: Cancer & Oncology Authors: Maximilian J. Mair Rupert Bartsch Emilie Le Rhun Anna S. Berghoff Priscilla K. Brastianos Javier Cortes Hui K. Gan Nancy U. Lin Andrew B. Lassman Patrick Y. Wen Michael Weller Martin van den Bent Matthias Preusser Source Type: research
CAR T cells induce durable remission of neuroblastoma
Nature Reviews Clinical Oncology, Published online: 20 April 2023; doi:10.1038/s41571-023-00768-9CAR T cells induce durable remission of neuroblastoma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 20, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Long-term outcomes following CAR T cell therapy: what we know so far
Nature Reviews Clinical Oncology, Published online: 13 April 2023; doi:10.1038/s41571-023-00754-1Chimeric antigen receptor (CAR) T cells have dramatically improved the outcomes of patients with certain relapsed and/or refractory haematological malignancies. Owing to the promising short-term survival outcomes achieved, long-term data on both safety and survival are becoming increasingly relevant. In this Review, the authors describe the available long-term follow-up data from early studies testing the safety and efficacy of receiving CAR T cells targeting CD19 as well as more recent data on BCMA-targeted CAR T cells in pati...
Source: Nature Reviews Clinical Oncology - April 13, 2023 Category: Cancer & Oncology Authors: Kathryn M. Cappell James N. Kochenderfer Source Type: research
Envisioning trans-inclusive and trans-specific cancer care
Nature Reviews Clinical Oncology, Published online: 12 April 2023; doi:10.1038/s41571-023-00764-zTransgender patients are a marginalized group for whom current standards of oncology have yet to be optimized. In this Comment, we highlight opportunities for transgender-inclusive and transgender-specific practices across the cancer care continuum and identify evidence gaps that will need to be filled to attain optimal care for transgender populations. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 12, 2023 Category: Cancer & Oncology Authors: Elle Lett Joannie M. Ivory Mya L. Roberson Source Type: research
New combination therapy for advanced-stage RCC
Nature Reviews Clinical Oncology, Published online: 11 April 2023; doi:10.1038/s41571-023-00765-yNew combination therapy for advanced-stage RCC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 11, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis
Nature Reviews Clinical Oncology, Published online: 11 April 2023; doi:10.1038/s41571-023-00762-1Immune-checkpoint-inhibitor-associated myocarditis has a high fatality rate, warranting the development of more-effective treatment strategies. Herein, we discuss a recent report of a series of patients who were managed using a novel approach that involved personalized abatacept dosing, ruxolitinib and close respiratory monitoring, which was associated with low mortality. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - April 11, 2023 Category: Cancer & Oncology Authors: Douglas B. Johnson Alexander M. Menzies Source Type: research
